Effects of levosimendan on ventriculo-arterial coupling and cardiac efficiency in paediatric patients with single-ventricle physiology after surgical palliation: retrospective study.
Cardiac Output, Low
/ drug therapy
Cardiotonic Agents
/ therapeutic use
Echocardiography
Female
Heart Failure
/ drug therapy
Humans
Hypoplastic Left Heart Syndrome
/ surgery
Infant
Infant, Newborn
Male
Retrospective Studies
Simendan
/ therapeutic use
Stroke Volume
/ drug effects
Univentricular Heart
/ surgery
Ventricular Function, Left
/ physiology
Levosimendan
Paediatric cardiac surgery
Palliative surgery
Univentricular heart
Ventriculo-arterial coupling
Journal
Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
05
11
2019
revised:
12
12
2019
accepted:
19
12
2019
pubmed:
28
1
2020
medline:
31
12
2020
entrez:
28
1
2020
Statut:
ppublish
Résumé
The use of levosimendan for paediatric patients with low cardiac output after congenital heart surgery has been recently described. We sought to evaluate ventriculo-arterial coupling (VAC) and other ventricular energetic parameters before and after 72 h from levosimendan start in infants with single-ventricle physiology and cardiac failure after palliation with Norwood or hybrid procedures. In this single-centre retrospective study, 9 consecutive patients affected by hypoplastic left heart syndrome-like anatomy were retrospectively analysed. Systolic elastance, diastolic elastance, arterial elastance, VAC and cardiac mechanical efficiency were calculated by measuring, through 2-dimensional echocardiography, end-systolic volume and end-diastolic volume and by recording mean arterial pressure and central venous pressure. The median (range) weight and age were 2.8 (2.3-6) kg and 16.5 (6-116) days, respectively. After 72 h from levosimendan start, end-systolic volume significantly decreased (-1 ml, -3.2 to -0.1, P = 0.007), whereas mean arterial pressure and end-diastolic volume remained stable. Heart rate showed a significant decrease (-28 beats/min, -41 to 22, P = 0.008). Systolic elastance (2.9 mmHg/ml, 0.4-5.4, P = 0.008), arterial elastance (-5.9, -24 to -0.5, P = 0.038), VAC (-0.86, -1.5 to -0.16, P = 0.009) and cardiac mechanical efficiency (0.18, 0.03-0.22, P = 0.008) differences also showed significant modifications. In a small case series of patients with single-ventricle physiology, levosimendan showed to improve contractility and optimize VAC, with a reduction of heart rate. Monitoring of VAC and ventricular energetics can be an interesting aspect to improve the management of heart failure in infants with univentricular anatomy.
Identifiants
pubmed: 31986196
pii: 5716380
doi: 10.1093/icvts/ivz319
doi:
Substances chimiques
Cardiotonic Agents
0
Simendan
349552KRHK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-629Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.